Announced Mon, 20 Jul · 16:18 IST
Emcure to offer Poviztra for MASH liver disease after CDSCO nod
Compliance View source PDF
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.0%1-day move
₹1862.00
prior close
₹1879.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0+0.3+0.4+0.1+1.0+0.6+1.1+2.9——————
Up moveDown movePending
AI summary
CDSCO approved innovator semaglutide for non-cirrhotic MASH with moderate to advanced liver fibrosis. Emcure will offer this through its co-marketed brand Poviztra, making semaglutide the first and only GLP-1 agonist approved in India for this condition. Phase III ESSENCE trial showed 63 percent steatohepatitis resolution and 37 percent fibrosis improvement. Distribution will use subsidiary Zuventus Healthcare's gastroenterology and hepatology network.
Likely market impact
Positive. Expands addressable market for Poviztra with first mover advantage in MASH treatment in India via Zuventus sales reach.